[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100377426":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Metabolic Patient",null,"Patients with a metabolic desease, defined as\n\n1. Metabolic Syndrom\n2. Diabetic\n3. Obese",[13],{"name":14,"affiliation":5,"role":15},"François Pattou, MD,PhD","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":20,"email":21},"CONTACT","03 20 44 42 73","+33","francois.pattou@chru-lille.fr",[23,36,47],{"facility":24,"status":25,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"Ch Boulogne-Sur-Mer","RECRUITING","Boulogne-sur-Mer","59037","France","FR",{"type":31,"coordinates":32},"Point",[33,34],1.61373,50.72485,{"lat":34,"lon":33},{"facility":37,"status":25,"city":38,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":39,"geoPoint":43,"contacts":44},"Hop Cardiologique Chr Lille","Lille",{"type":31,"coordinates":40},[41,42],3.05512,50.63391,{"lat":42,"lon":41},[45],{"name":10,"role":18,"phone":46,"phoneExt":10,"email":10},"0320445962",{"facility":48,"status":25,"city":38,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},"Hop Claude Huriez Chr Lille",{"type":31,"coordinates":50},[41,42],{"lat":42,"lon":41},[53],{"name":10,"role":18,"phone":46,"phoneExt":10,"email":10},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100377426","signature-of-the-risk-profile-of-mortality-in-a-hospital-cohort-of-patients-with-metabolic-diseases-100377426",false,"NCT04194372","Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases","INTEGRA","Inclusion Criteria:\n\n* Diabetic: antecedent - treatment - or glycemia\\> = 1.26 g \u002F dl - or HbA1C\\> = 6.5% and or\n* Obese: BMI\\> = 30 and or\n* Metabolic syndrome defined AND\n* Patient having given written consent to participate in the study or collection of the consent of the witness\n* Social insured patient (excluding AME)\n* Patient willing to comply with all procedures of the study and its duration AND\n\nPatient also presenting a pathology among:\n\n* Cardiology:\n\n  * Coronary patient(history of myocardial infarction, coronary bypass, or coronary angioplasty or stenosis greater than 50% on an epicardial vessel documented on coronary angiography)\n  * Patient with systolic or diastolic heart failure\n  * Patient with atrial fibrillation\n  * Patient with aortic stenosis (Vmax\\> 2.5 m \u002F s)\n  * Patient with high blood pressure\n* neurology:\n\n  * ischemic stroke\n  * intracerebral hemorrhage\n  * transient ischemic attack\n* diabetology:\n\n  * Obesity without diabetes\n  * Diabetes T2\n  * T1 diabetes\n  * Monogenic Diabetes \u002F MODY\n  * African Diabetes\n  * Diabetes secondary to pancreatopathy \u002F liver cirrhosis\n  * Diabetes post transplantation \u002F post immunotherapy\n  * Diabetes associated with Steinert's disease\n* hepatology: hepatological pathology\n* nephrology: nephrology\n\nExclusion Criteria:\n\n* Unscheduled hospitalization less than 3 months old\n* Ongoing treatment :\n\n  * Cytotoxic chemotherapy\n  * Radiotherapy\n* HIV and \u002F or HCV and \u002F or active HBV infection\n* OMS score\\> = 2\n* Pregnant woman","ALL","18 Years",{"count":66,"type":67},10000,"ESTIMATED","OBSERVATIONAL","Epidemiological studies are usually conducted in the general population in adults without complications or pathology at baseline. The results obtained are therefore often better designed for primary prevention use. The prediction of mortality risk in patients with complications and requiring hospital follow-up is less well known.\n\nThe study purpose is to determine a mortality risk profile in a hospital cohort of patients with pathologies associated with metabolic diseases.\n\nToday the \"multimaker\" scores based on a panel of biomarkers - have significantly improved the discriminating power of prediction models existing in many pathologies. It is no longer a single biomarker that can improve risk prediction but a complete and cross-sectional profile that is sought after. We aim to establish a personalised mortality risk profile by combining clinical and biological parameters including metabolomics, genetics, transcriptomics and epigenomics by high throughput screening of biological samples.",[71],"Metabolic Disease",[73,74,75,76],"Diabetic","CardioVascular Disease","morbi-mortality","Hospital Cohort","2026-05-20",{"date":79,"type":80},"2026-05-22","ACTUAL",{"date":82,"type":80},"2019-12-20",{"date":84,"type":67},"2030-01",{"name":5,"class":6},3]